Dr. Sue Kim, Ph.D., is the founder and CEO of Brexogen Inc., one of the leading biotechnology company specializing in stem cell research and exosome based therapeutics and aesthetic products. With an academic background rooted in biotechnology and animal science, Dr. Kim earned her Ph.D. in Theriogenology and Biotechnology from Seoul National University, following her B.S. in Animal Science from Konkuk University. Over the past two decades, she has built a distinguished career in both academia and the biotechnology industry, focusing on regenerative medicine and exosome research.
Since founding Brexogen in 2019, Dr. Kim has led a multidisciplinary team focused on developing novel stem cell and exosome-based therapies and aesthetics, particularly targeting skin regeneration, cardiac repair, and the treatment of inflammatory diseases such as atopic dermatitis. Her recent work has centered on the therapeutic potential of iMSC-derived exosomes, particularly in enhancing skin barrier function and mitigating inflammatory responses. One of her notable contributions is the development of exosome therapies for conditions like atopic dermatitis and wound healing, where her research demonstrated that extracellular vesicles derived from IFN-γ-primed iMSCs (BxC-I17e) could significantly improve skin inflammation and repair processes. Dr. Kim's extensive publication record highlights her contributions to the field of regenerative medicine, with recent studies detailing the application of stem cell-derived exosomes in treating acute kidney injury and nonalcoholic steatohepatitis. Through her work, Dr. Kim has established Brexogen as a leader in the field of exosome research, driving innovation with a focus on clinical applications. Her pioneering efforts in the development of iMSC-based therapies have positioned Brexogen at the cutting edge of biotechnology, contributing to the broader scientific understanding of stem cell biology and offering new avenues for the treatment of various chronic conditions.